{"transactions":[{"id":794166,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-05-04T22:02:53.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":false,"shares":2681265,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2681265},"source":{"system":"sec-edgar","filing":"0001193125-26-204458","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204458/ownership.xml","form_type":"4"}},{"id":794165,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2026-05-04T22:02:53.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":false,"shares":2513686,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2513686},"source":{"system":"sec-edgar","filing":"0001193125-26-204458","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204458/ownership.xml","form_type":"4"}},{"id":794164,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T22:02:53.000Z","date":"2026-05-04","kind":"purchase","planned":false,"acquired":true,"shares":1100000,"price":18,"value":19800000.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":6294951,"source":{"system":"sec-edgar","filing":"0001193125-26-204458","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204458/ownership.xml","form_type":"4"}},{"id":794163,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T22:02:53.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":true,"shares":2681265,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":5194951,"source":{"system":"sec-edgar","filing":"0001193125-26-204458","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204458/ownership.xml","form_type":"4"}},{"id":794162,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T22:02:53.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":true,"shares":2513686,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":2513686,"source":{"system":"sec-edgar","filing":"0001193125-26-204458","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204458/ownership.xml","form_type":"4"}},{"id":999081,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-14T18:34:16.000Z","date":"2025-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8313680,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"date","element":"transactionDate","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by ARCH Venture Fund XIII, L.P. (\"ARCH Venture Fund XIII\").  ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII.  ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII.  AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell and Robert Nelsen (the \"AVP XIII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares.  Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001012975-25-000791","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000101297525000791/form4.xml","form_type":"4"}},{"id":999080,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-14T18:34:16.000Z","date":"2025-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18503128,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"date","element":"transactionDate","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\").  ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares.  Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001012975-25-000791","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000101297525000791/form4.xml","form_type":"4"}},{"id":1012114,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":7,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-29T23:21:13.000Z","date":"2025-10-27","kind":"purchase","planned":false,"acquired":true,"shares":1915700,"price":2.61,"value":4999977.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":6046907,"source":{"system":"sec-edgar","filing":"0001012975-25-000680","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000101297525000680/form4.xml","form_type":"4"}},{"id":1077713,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-01T23:19:33.000Z","date":"2025-08-01","kind":"purchase","planned":false,"acquired":true,"shares":3030300,"price":3.3,"value":9999990.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":6230300,"source":{"system":"sec-edgar","filing":"0001062993-25-013461","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000106299325013461/form4.xml","form_type":"4"}},{"id":1287653,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":2678571,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund XIII, L.P.(\"ARCH Venture Fund XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XIII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from footnote 3)  Each of Kristina Burow and Paul Berns has filed a separate Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1139951},"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1287652,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":15000000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund XIII, L.P.(\"ARCH Venture Fund XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XIII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from footnote 3)  Each of Kristina Burow and Paul Berns has filed a separate Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6383731},"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1287651,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":2678571,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\").  ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares.  Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1139951},"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1287650,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":15000000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\").  ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares.  Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6383730},"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1287649,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":19933333,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\").  ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares.  Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8483268},"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1287648,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"purchase","planned":false,"acquired":true,"shares":789998,"price":18,"value":14219964.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund XIII, L.P.(\"ARCH Venture Fund XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XIII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from footnote 3)  Each of Kristina Burow and Paul Berns has filed a separate Form 4."}],"balance_after":8313680,"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1287647,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"purchase","planned":false,"acquired":true,"shares":1432224,"price":18,"value":25780032.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\").  ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares.  Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":18503128,"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1287646,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":true,"shares":7523682,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund XIII, L.P.(\"ARCH Venture Fund XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XIII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from footnote 3)  Each of Kristina Burow and Paul Berns has filed a separate Form 4."}],"balance_after":7523682,"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1287645,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":true,"shares":16006949,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\").  ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares.  Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":17070904,"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1485283,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-06-10T23:46:32.000Z","date":"2024-06-10","kind":"exercise","planned":false,"acquired":false,"shares":11924138,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1392738},"source":{"system":"sec-edgar","filing":"0000950170-24-071543","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024071543/ownership.xml","form_type":"4"}},{"id":1485282,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2024-06-10T23:46:32.000Z","date":"2024-06-10","kind":"exercise","planned":false,"acquired":false,"shares":20000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2336000},"source":{"system":"sec-edgar","filing":"0000950170-24-071543","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024071543/ownership.xml","form_type":"4"}},{"id":1485281,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-10T23:46:32.000Z","date":"2024-06-10","kind":"exercise","planned":false,"acquired":true,"shares":3728738,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":3728738,"source":{"system":"sec-edgar","filing":"0000950170-24-071543","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024071543/ownership.xml","form_type":"4"}},{"id":1634285,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-20T22:38:59.000Z","date":"2024-02-15","kind":"purchase","planned":false,"acquired":true,"shares":3200000,"price":6.25,"value":20000000.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":3200000,"source":{"system":"sec-edgar","filing":"0001062993-24-003739","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000106299324003739/form4.xml","form_type":"4"}},{"id":1714601,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":7,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-13T00:53:13.000Z","date":"2023-12-08","kind":"other","planned":false,"acquired":true,"shares":1176593,"ownership":{"direct":false,"nature":"By ARCH Venture Fund VIII Overage, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer.  Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to  former stockholders of BlackThorn Therapeutics upon satisfaction of certain contractual milestones.  Shares were received without any action by Reporting Persons.  No additional consideration was paid for the shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":2321566,"source":{"system":"sec-edgar","filing":"0001062993-23-022481","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323022481/form4.xml","form_type":"4"}},{"id":1714600,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":7,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-13T00:53:13.000Z","date":"2023-12-08","kind":"other","planned":false,"acquired":true,"shares":703061,"ownership":{"direct":false,"nature":"By ARCH Venture Fund VII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer.  Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to  former stockholders of BlackThorn Therapeutics upon satisfaction of certain contractual milestones.  Shares were received without any action by Reporting Persons.  No additional consideration was paid for the shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer.  Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to  former stockholders of BlackThorn Therapeutics upon satisfaction of certain contractual milestones.  Shares were received without any action by Reporting Persons.  No additional consideration was paid for the shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1387228,"source":{"system":"sec-edgar","filing":"0001062993-23-022481","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323022481/form4.xml","form_type":"4"}},{"id":1740990,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-15T23:54:20.000Z","date":"2023-11-14","kind":"purchase","planned":false,"acquired":true,"shares":3357,"price":11.98,"value":40216.86,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.89 to $12.00, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Beneficial ownership consists of 4,131,207 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":4131207,"source":{"system":"sec-edgar","filing":"0001062993-23-020933","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020933/form4.xml","form_type":"4"}},{"id":1740989,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-15T23:54:20.000Z","date":"2023-11-13","kind":"purchase","planned":false,"acquired":true,"shares":31653,"price":11.75,"value":371922.75,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.52 to $12.00, inclusive.  The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Beneficial ownership consists of 4,131,207 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":4127850,"source":{"system":"sec-edgar","filing":"0001062993-23-020933","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020933/form4.xml","form_type":"4"}},{"id":1744258,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-14T00:00:04.000Z","date":"2023-11-10","kind":"purchase","planned":false,"acquired":true,"shares":5431,"price":11.75,"value":63814.25,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.63 to $11.8922, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":4096197,"source":{"system":"sec-edgar","filing":"0001062993-23-020712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020712/form4.xml","form_type":"4"}},{"id":1744257,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-14T00:00:04.000Z","date":"2023-11-10","kind":"purchase","planned":false,"acquired":true,"shares":11844,"price":11.37,"value":134666.28,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $10.62 to $11.61, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":4090766,"source":{"system":"sec-edgar","filing":"0001062993-23-020712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020712/form4.xml","form_type":"4"}},{"id":1744256,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-14T00:00:04.000Z","date":"2023-11-09","kind":"purchase","planned":false,"acquired":true,"shares":31079,"price":10.53,"value":327261.87,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $10.445 to $10.7975, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":4078922,"source":{"system":"sec-edgar","filing":"0001062993-23-020712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020712/form4.xml","form_type":"4"}},{"id":1744255,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-14T00:00:04.000Z","date":"2023-11-08","kind":"purchase","planned":false,"acquired":true,"shares":23124,"price":11.79,"value":272631.96,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.5007 to $12.00, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":4047843,"source":{"system":"sec-edgar","filing":"0001062993-23-020712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020712/form4.xml","form_type":"4"}},{"id":1744254,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-14T00:00:04.000Z","date":"2023-11-08","kind":"purchase","planned":false,"acquired":true,"shares":69127,"price":10.78,"value":745189.06,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $10.50 to $11.4891, inclusive.  The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4) and (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":4024719,"source":{"system":"sec-edgar","filing":"0001062993-23-020712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020712/form4.xml","form_type":"4"}},{"id":1747753,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-07T23:59:41.000Z","date":"2023-11-07","kind":"purchase","planned":false,"acquired":true,"shares":30192,"price":11.5,"value":347208.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.34 to $11.67, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,955,592 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3955592,"source":{"system":"sec-edgar","filing":"0001062993-23-020279","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020279/form4.xml","form_type":"4"}},{"id":1747752,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-07T23:59:41.000Z","date":"2023-11-06","kind":"purchase","planned":false,"acquired":true,"shares":43082,"price":11.55,"value":497597.1,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.34 to $11.99, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,955,592 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3925400,"source":{"system":"sec-edgar","filing":"0001062993-23-020279","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020279/form4.xml","form_type":"4"}},{"id":1747751,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-07T23:59:41.000Z","date":"2023-11-03","kind":"purchase","planned":false,"acquired":true,"shares":22420,"price":11.38,"value":255139.6,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.08 to $11.82, inclusive.  The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,955,592 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3882318,"source":{"system":"sec-edgar","filing":"0001062993-23-020279","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020279/form4.xml","form_type":"4"}},{"id":1771636,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-29T22:53:23.000Z","date":"2023-09-29","kind":"purchase","planned":false,"acquired":true,"shares":34560,"price":13.98,"value":483148.8,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $13.48 to $14.11, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,859,898 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3859898,"source":{"system":"sec-edgar","filing":"0001062993-23-018632","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323018632/form4.xml","form_type":"4"}},{"id":1771635,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-29T22:53:23.000Z","date":"2023-09-28","kind":"purchase","planned":false,"acquired":true,"shares":25110,"price":13.69,"value":343755.9,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $13.34 to $14.23, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,859,898 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3825338,"source":{"system":"sec-edgar","filing":"0001062993-23-018632","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323018632/form4.xml","form_type":"4"}},{"id":1771634,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-29T22:53:23.000Z","date":"2023-09-28","kind":"purchase","planned":false,"acquired":true,"shares":16841,"price":13.06,"value":219943.46,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $12.34 to $13.33, inclusive.  The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,859,898 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3800228,"source":{"system":"sec-edgar","filing":"0001062993-23-018632","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323018632/form4.xml","form_type":"4"}},{"id":1772679,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-28T00:18:52.000Z","date":"2023-09-27","kind":"purchase","planned":false,"acquired":true,"shares":24504,"price":12.31,"value":301644.24,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.94 to $12.68, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Beneficial ownership consists of 3,783,387 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3783387,"source":{"system":"sec-edgar","filing":"0001062993-23-018547","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323018547/form4.xml","form_type":"4"}},{"id":1772678,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-28T00:18:52.000Z","date":"2023-09-26","kind":"purchase","planned":false,"acquired":true,"shares":34000,"price":11.73,"value":398820.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.32 to $12.04, inclusive.  The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Beneficial ownership consists of 3,783,387 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3758883,"source":{"system":"sec-edgar","filing":"0001062993-23-018547","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323018547/form4.xml","form_type":"4"}},{"id":1774052,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-26T01:38:12.000Z","date":"2023-09-25","kind":"purchase","planned":false,"acquired":true,"shares":29967,"price":11.65,"value":349115.55,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.50 to $12.14, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,724,883 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3724883,"source":{"system":"sec-edgar","filing":"0001062993-23-018469","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323018469/form4.xml","form_type":"4"}},{"id":1774051,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-26T01:38:12.000Z","date":"2023-09-25","kind":"purchase","planned":false,"acquired":true,"shares":30773,"price":10.8,"value":332348.4,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $10.50 to $11.49, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,724,883 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3694916,"source":{"system":"sec-edgar","filing":"0001062993-23-018469","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323018469/form4.xml","form_type":"4"}},{"id":1774050,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-26T01:38:12.000Z","date":"2023-09-22","kind":"purchase","planned":false,"acquired":true,"shares":40000,"price":11.14,"value":445600.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $10.50 to $11.48, inclusive.  The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,724,883 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3664143,"source":{"system":"sec-edgar","filing":"0001062993-23-018469","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323018469/form4.xml","form_type":"4"}},{"id":1776339,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":2124143,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2124143},"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776338,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":6576400,"ownership":{"direct":false,"nature":"By ARCH Venture Fund X Overage, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6576400},"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776337,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":6895021,"ownership":{"direct":false,"nature":"By ARCH Venture Fund X, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6895021},"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776336,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":1144973,"ownership":{"direct":false,"nature":"By ARCH Venture Fund VIII Overage, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1144973},"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776335,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":684167,"ownership":{"direct":false,"nature":"By ARCH Venture Fund VII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":684167},"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776334,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"purchase","planned":false,"acquired":true,"shares":1500000,"price":17,"value":25500000.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":3624143,"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776333,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":2124143,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":2124143,"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776332,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":6576400,"ownership":{"direct":false,"nature":"By ARCH Venture Fund X Overage, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any."}],"balance_after":11886758,"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776331,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":6895021,"ownership":{"direct":false,"nature":"By ARCH Venture Fund X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any."}],"balance_after":12205379,"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776330,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":1144973,"ownership":{"direct":false,"nature":"By ARCH Venture Fund VIII Overage, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1144973,"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776329,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":684167,"ownership":{"direct":false,"nature":"By ARCH Venture Fund VII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":684167,"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}}]}